PEG-75 Lanolin Pharma Grade API is a high-ethoxylation lanolin derivative manufactured by alkali-catalysed addition of a nominal 75 moles of ethylene oxide per mole of pharmaceutical-grade lanolin backbone; the commonly assigned CAS RN is 61790-81-6. Supplier model designations vary, but the grade is identified by its average ethoxylation ratio rather than by a single molecular mass, because the ethoxylation reaction produces a distribution of oligomers. The pharmaceutical monograph-style specification is centred on HLB 15.0–16.5, water dispersibility, low residual ethylene oxide, and low endotoxin burden when ordered as a parenteral-grade input. The material is nonionic, waxy at room temperature, and functions as an aqueous wetting agent, O/W emulsifier, and granulation binder rather than as a pharmacologically active species. In oral solid dosage, it is introduced as a pre-dispersed aqueous phase or as a meltable binder; in injectable development, its use is constrained by particulate, pyrogen, and oxidative stability requirements.

What Distinguishes the Pharma Grade from Technical and Cosmetic Lanolin Ethoxylates?

The pharma grade is differentiated by residual monomer control, elemental impurity testing, microbial burden, and endotoxin control. Technical ethoxylates may contain free ethylene oxide above 10 ppm; the pharma grade is released against a residual ethylene oxide limit of ≤1 ppm and 1,4-dioxane ≤10 ppm using validated GC-HS methods aligned with USP <228> and ICH Q3C. Heavy metals are tested under USP <232> and <233> against ICH Q3D; microbial quality is assessed by USP <61> and <62> with total aerobic microbial count controlled to ≤100 CFU/g and combined yeast and mold to ≤10 CFU/g. For injectable grade, bacterial endotoxins are measured by USP <85>; a common provisional limit is ≤0.5 EU/mg, but the final limit must be derived from the maximum human dose and the finished product monograph. Cosmetic grades do not normally carry these release obligations and may be supplied with higher peroxide values, broader oligomer distribution, and greater colour intensity.

On a rotary tablet press operating at 40–60 rpm with compression force 8–15 kN and pre-compression 2–4 kN, granulations containing 1.0–3.0% w/w PEG-75 Lanolin are processed with reduced picking when the press feed frame and punch tips are maintained below 35 °C. The lanolin ethoxylate softens above approximately 40 °C; therefore compression dwell settings and turret speed should be selected to limit frictional heating. Dissolution performance is not assumed from HLB alone; it is evaluated in USP apparatus II at 50 rpm in 900 mL of pH 1.2, 4.5, and 6.8 media. Batches that release more than 5.0% free polyethylene glycol show variable granule friability, so free PEG is included in the supplier certificate for solid-dosage qualification.

Release Specification and Monograph Alignment for Oral and Parenteral Use

No dedicated USP–NF or Ph. Eur. monograph is published for PEG-75 Lanolin; the pharma-grade release profile is therefore assembled from applicable general chapters and supplier monographs. Published data for this specific configuration is limited. The following table summarises representative acceptance criteria.

The specification is not a monograph substitution. For injectable development, the applicant must establish that residual lanolin alcohol, free PEG, and sterol-derived impurities do not exceed toxicological qualification thresholds under ICH M7 and ICH Q3D. The supplier’s model-specific certificate of analysis should be mapped against the formulation’s impurity budget before lot acceptance.

When Tablet and Capsule Formulations Demand Low-Foaming Wetting Without Native Lanolin’s W/O Character

Native lanolin has a low HLB and is used as a W/O emulsifier or plasticiser; it is substantially water-insoluble at 25 °C. PEG-75 Lanolin shifts the hydrophilic–lipophilic balance by adding ethoxylate chains, giving it aqueous dispersibility and a function closer to polysorbate 80 or PEG-40 hydrogenated castor oil. In tablet and capsule wet granulation, the product is added at 0.5–3.0% w/w as an aqueous binder phase. It reduces surface tension of the granulation fluid and improves wetting of hydrophobic actives; the resulting granule size distribution is usually bimodal, with a target of 60–80% retained between 75 µm and 850 µm sieves after drying. Compared with sodium lauryl sulfate, the nonionic structure produces less pH-dependent foaming, but head-space foaming should still be measured using ASTM D1173 because the high-MW ethoxylate distribution can stabilise air bubbles in low-viscosity media.

High-shear wet granulation with a 10 L vertical granulator and chopper speed 1,500 rpm shows a narrow wet massing window. A binder dispersion at 2.0% w/w sprayed at 20–40 g/min into a 1.2 kg dry powder charge raises granule temperature by 3–5 °C; when product temperature exceeds 40 °C, the wax-like ethoxylate becomes tacky and impeller torque increases sharply from 18 N·m to 32 N·m in less than 60 s. The wet massing time is therefore limited to 90–180 s. Drying in a fluid-bed drier with inlet air at 55–65 °C and endpoint LOD ≤2.0% preserves granule compressibility; higher residual moisture promotes sticking during subsequent compression. These operating limits are equipment-dependent and should be re-established on the production-scale mixer by torque and temperature logging.

Dried granules containing PEG-75 Lanolin typically exhibit a Carr index 12–18% and Hausner ratio 1.10–1.20 when the binder is used at 2.0% w/w and dried to LOD 1.5–2.0%. Capsule filling on a dosing-disc capsule filler at 10,000–30,000 capsules/h is acceptable if granule moisture is below 2.0%; higher moisture causes powder adhesion to the dosing disc and shell embrittlement. Published data for this specific configuration is limited.

Does the Material Support Oral Liquids, Dispersible Tablets, and Enteric Granule Sealing?

In oral liquids and dispersible tablets, PEG-75 Lanolin functions as a nonionic solubiliser and matrix wetting agent at low inclusion. Aqueous dispersions are prepared by melting or softening the material at 40–50 °C and dispersing it into purified water under a low-shear impeller; final concentration is typically 0.5–2.0% w/w. Clarity and filterability decrease as the concentration approaches 3.0% w/w or as ionic strength rises. Solutions containing high salt levels or acidic buffers should be assessed for cloud point depression and phase separation; no fixed electrolyte ceiling is assigned because the cloud point depends on oligomer distribution. For enteric granule sealing, the material may act as a temporary hydrophobic carrier that delays water penetration in the uncoated state, but final enteric performance must be confirmed by USP dissolution in 0.1 N HCl for 2 h followed by pH 6.8 phosphate buffer. Published data for this specific configuration is limited.

Injectable-Grade Controls: Endotoxin, Particulate, and Sterile Filtration

Use in injectable formulations requires a dedicated parenteral-grade supply with controlled bioburden, endotoxin, and particulate load. Aqueous solutions at ≤2.0% w/w can be sterile-filtered through 0.22 µm hydrophilic PVDF or PES capsule filters if the solution is maintained at 35–40 °C; below 30 °C the ethoxylate dispersion may foul the membrane and reduce flux below practical production rates. Terminal autoclaving at 121 °C for 15 min may raise peroxide value and deepen colour, so aseptic filtration is preferred unless terminal sterilisation compatibility is demonstrated. Parenteral compounding should be conducted in an ISO 14644-1 Class 5 environment with terminal sterilising-grade filtration. Endotoxin control is managed at the supplier and the finished product: raw material release is provisionally set at ≤0.5 EU/mg, but the formulation limit must satisfy USP <85> for the maximum administered dose. Particulate quality is evaluated after filtration using USP <788>; because the product is a complex ethoxylated lanolin, subvisible particle counts in the concentrate should be validated before scale-up.

Differences from polysorbate 80 and PEG-40 hydrogenated castor oil are relevant when selecting a parenteral or oral wetting agent. Polysorbate 80 is synthetic, has HLB 15.0, and is available in multi-compendial parenteral grades; PEG-75 Lanolin retains sterol and terpene residues from the wool fat source and may introduce stronger colour and odour. PEG-40 hydrogenated castor oil is less odorous and often more oxidatively stable, but its solubilisation capacity for sterol-based actives differs. Lower ethoxylation grades such as PEG-30 lanolin have HLB below 12 and are not fully water-dispersible; PEG-75 is selected only when high aqueous compatibility is required. The trade-off is that the higher ethoxylation distribution increases the mass fraction of free polyethylene glycol, which can plasticise tablet films and reduce tensile strength if not controlled.

If Terminal Sterilisation Is Required, Oxidative Degradation Must Be Monitored

Autoclaving at 121 °C for 15 min is the main incompatibility test for nonionic ethoxylates. Heat and residual oxygen increase peroxide value; a pharma-grade lot may have an initial peroxide value below 1.0 meq/kg, but terminal steam sterility can raise it above 5.0 meq/kg unless an oxygen-free headspace is maintained. The grade should be stored under nitrogen in closed, moisture-tight containers at ≤25 °C, protected from light; retest intervals of 12 months are typical for peroxide value and moisture. Avoid combination with strong oxidising preservatives, peroxides, and extremes below pH 2.0 or above pH 10.0 in aqueous systems because ester and ether hydrolysis can alter HLB and generate free lanolin alcohol. In capsule and tablet operations, exposure to prolonged direct sunlight accelerates colour shift from pale yellow to amber; opaque secondary packaging is recommended for finished products containing this material.

For granule, tablet, and capsule process design, the critical control points are binder dispersion temperature, wet massing time, dryer LOD, and compression zone temperature. Batch-to-batch variance in lanolin raw material can alter the oligomer distribution and odour profile; a vendor change should trigger a full re-evaluation of the granulation endpoint and the dissolution profile. Because published data for this specific configuration is limited, formulation-specific qualification under ICH Q1A, USP apparatus reliability, and process temperature mapping are required before commercial batch release. Stability batches should include inverted tablet containers and hard gelatin capsule shells stored at 40 °C/75% RH for at least 6 months to detect moisture transfer from the ethoxylate phase.